Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.43 |
| ▸ | TLR2 | O60603 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2302847 | 0.95 | KMT2A (0.52) | KMT2AEPHX2CHRM3CHRM1CHRM2 | |
| Hydrochloric Acid SCHEMBL30901456 | 0.94 | KMT2A (0.51) | KMT2AEPHX2CHRM3CHRM1CHRM2 | |
| Hydrochloric Acid SCHEMBL1560621 | 0.94 | KMT2A (0.51) | KMT2AEPHX2CHRM3CHRM1CHRM2 | |
| SCHEMBL23841210 | 0.89 | KMT2A (0.56) | KMT2AEPHX2EPHX1 | |
| SCHEMBL10230770 | 0.87 | KMT2A (0.54) | KMT2AEPHX2EPHX1 | |
| SCHEMBL13020974 | 0.87 | KMT2A (0.54) | KMT2AEPHX2EPHX1 | |
| SCHEMBL13555711 | 0.87 | KMT2A (0.54) | KMT2AEPHX2EPHX1 | |
| SCHEMBL16248428 | 0.87 | KMT2A (0.54) | KMT2AEPHX2EPHX1 | |
| SCHEMBL471502 | 0.87 | KMT2A (0.54) | KMT2AEPHX2EPHX1 | |
| SCHEMBL15705238 | 0.87 | KMT2A (0.54) | KMT2AEPHX2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012123298-A1 | ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-20 | — | — | WO | disclosed |
| US-6656911-B2 | Oxadiazole ring structure peptoids which are useful as inhibitors of serine proteases | CORTECH, INC. | 2003-12-02 | — | — | US | disclosed |
| US-20030203851-A1 | Substituted oxadiazole, peptoids which are useful for treating adult respiratory distress syndrome, septic shock and myocardial ischemia-reperfusion injury | CORTECH, INC. | 2003-10-30 | — | — | US | disclosed |
| US-20020119985-A1 | Serine protease inhibitors | CORTECH, INC. | 2002-08-29 | — | — | US | disclosed |
| US-5998379-A | USEFUL AS INHIBITORS OF SERINE PROTEASES, IN PARTICULAR HUMAN NEUTROPHIL ELASTASE, TREATMENT OF ADULT RESPIRATORY DISTRESS SYNDROME, SEPTIC SHOCK, AND MYOCARDIAL ISCHEMIA-REPERFUSION INJURY | CORTECH INC. (US) | 1999-12-07 | — | — | US | disclosed |
| EP-0954526-A2 | SERINE PROTEASE INHIBITORS | CORTECH, INC. (US) | 1999-11-10 | — | — | EP | disclosed |
| WO-1998024806-A2 | SUBSTITUTED OXADIAZOLE, THIADIAZOLE AND TRIAZOLE SERINE PROTEASE INHIBITORS | CORTECH, INC. (US) | 1998-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119985-A1 | Serine protease inhibitors | PRSS1, SERPINB1, SERPINE1 | KMT2A 4782/4885EPHX2 2913/4885CHRM3 4360/4885 |
| US-20030203851-A1 | Substituted oxadiazole, peptoids which are useful for treating adult respiratory distress syndrome, septic shock and myocardial ischemia-reperfusion injury | TNNI3, PEPD, STK35 | KMT2A 4854/4885EPHX2 2845/4885CHRM3 3113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.